Last reviewed · How we verify
ERLOTINIB
ERLOTINIB is a drug. It is currently FDA-approved (first approved 2004).
Erlotinib is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) used to treat various conditions, including Stage III Non-Small Cell Lung Cancer, Pancreatic Cancer, and Age-Related Macular Degeneration. It is often used in combination with other treatments such as radiation therapy and chemotherapy agents like carboplatin and cisplatin.
At a glance
| Generic name | ERLOTINIB |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
Common side effects
Key clinical trials
- Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors (PHASE1)
- Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (PHASE1)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
- GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (PHASE1)
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ERLOTINIB CI brief — competitive landscape report
- ERLOTINIB updates RSS · CI watch RSS
Frequently asked questions about ERLOTINIB
What is ERLOTINIB?
When was ERLOTINIB approved?
What development phase is ERLOTINIB in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing